ascendance biotechnology other cell cure neurosciences ltd. lifemap sciences orthocyte recyte therapeutics inc. careers other partnerships patent portfolio glossary videos update series investor & corporate updates science & technologies products & pipeline aesthetics renevia ophthalmics opregen other immunotherapy ast vac1 & ast vac2 spinal cord injury ast opc1 mhealth research products other cancer diagnostics genecards suite hextend purestem progenitors technologies purestem progenitors hystem hydrogels regenerative medicine cancer diagnostics core technologies scientific publications investors & media press releases events & presentations corporate governance analyst coverage stock information financials & filings e mail alerts contact ir contact us 0 no products in the cart . search leading the regenerative medicine revolution pursuing cures for degenerative diseases advancing clinical trials on multiple platforms cell therapies aesthetics ophthalmics targeting root causes and potential cures regenerative technologies our focus biotime is building a dominant company in the field of regenerative medicine . our strategy is to be the leader in the development of pluripotent stem cell based technologies and to apply those new technologies in the treatment of degenerative diseases that afflict large numbers of people worldwide . we have advanced additional products into human clinical trials over the past year . we are committed to leading the regenerative medicine revolution to realize the promise of our revolutionary therapies . by advancing the development of our clinical products and technologies our goal is to find cures for serious degenerative diseases that afflict people worldwide . through the commitment from our family of companies and our dedicated scientists and employees we are working to bring revolutionary new regenerative medicines to patients with chronic and degenerative diseases . more videos latest news biotime to present at the bio investor forum october 13 2016 biotime to webcast presentation at the ladenburg thalmann 2016 healthcare conference september 23 2016 biotime affiliate asterias biotherapeutics announced positive interim efficacy data from trial in patients with complete cervical spinal cord injuries september 15 2016 more news events biotime inc. at bio investor forum october 19 2016 more events a nearly three decade long stem cell tale in california sep 28th 2016 our focus leading the regenerative medicine revolution jun 12th 2015 1010 atlantic avenue 102 alameda ca 94501 510 521 3390 info biotimeinc.com connect copyright 2016 biotime inc. home company products & pipeline technologies investors & media contact us